Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria

Free Radical Biology and Medicine

Volumn 30, Issue 8, 2001, Pages 924-931

  Kristal, Bruce S ^a,b   Conway, Ann D ^c   Brown, Abraham M ^a,b   Jain, Jinesh C ^d   Ulluci, Paul A ^e   Li, Shu Wen ^f   Burke, William J ^c  

^a BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d University of Notre Dame   (United States)

^e ESA Biosciences Inc   (United States)

^f Saint Louis University   (United States)

Author keywords

Dopamine; Free radicals; Mitochondria; Parkinson's disease; Permeability transition; Reactive species

Indexed keywords

3,4 DIHYDROPHENYLACETALDEHYDE; DOPAMINE; LEVODOPA; MONOAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL STRAIN; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC SYSTEM; MALE; METABOLITE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; 4-AMINOBENZOIC ACID; ANIMALS; ARISTOLOCHIC ACIDS; CELL DEATH; CELL DIFFERENTIATION; CYCLOSPORINE; DOPAMINE; DOPAMINE ANTAGONISTS; ENZYME INHIBITORS; ION CHANNELS; MALE; MEMBRANE PROTEINS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NERVE GROWTH FACTOR; PARKINSON DISEASE; PC12 CELLS; PHENANTHRENES; RATS; RATS, INBRED F344; RESPIRATION; ROTENONE; TRIFLUOPERAZINE; UNCOUPLING AGENTS;

GYMNOMYZA SAMOENSIS;

EID: 0035871771     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(01)00484-1     Document Type: Article

References (65)

1. Parkinson's disease: A new link between monoamine oxidase and mitochondrial electron flow
2. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
3. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
4. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
5. Abnormalities of the electron transport chain in idiopathic Parkinson's disease
6. Mitochondrial complex I deficiency in Parkinson's disease
7. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
8. Mitochondrial oxidative phosphorylation defects in Parkinson's disease
9. Mitochondria and cell death: Mechanistic aspects and methodological issues
10. Mitochondria and apoptosis
11. Role of the mitochondrial permeability transition pore in apoptosis
12. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy
13. Mitochondria as regulators of apoptosis: Doubt no more
14. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde
15. Amine oxidase and amine metabolism
16. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: A mechanism for DOPEGAL-induced apoptosis
17. Norepinephrine transmitter metabolite induces apoptosis in differentiated rat pheochromocytoma cells
18. Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells
19. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition
20. Differential effect of dopamine catabolism and uptake inhibition on dopamine-induced calcium dysregulation and viability loss
21. Dopamine-induced apoptosis is inhibited in PC12 cells expressing bcl-2
22. Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde
23. Dietary restriction enhances resistance to oxidant-mediated inhibition of mitochondrial transcription
24. Purine catabolism: Links to mitochondrial respiration and antioxidant defenses?
25. Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition
26. ++ inhibits a-ketoglutarate-stimulated mitochondrial respiration and the isolated a-ketoglutarate dehydrogenase complex
27. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which responds to nerve growth factor
28. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
29. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high performance liquid chromatography
30. Mitochondrial permeability transition in the central nervous system: Induction by calcium-cycling dependent and independent pathways
31. Mitochondria and neuronal survival
32. 2+ transients
33. Coupling between cytosolic and mitochondrial calcium oscillations: Role in the regulation of hepatic metabolism
34. From calcium signaling to cell death: Two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state
35. The mitochondrial permeability transition
36. Mitochondrial calcium transport: Physiological and pathological evidence
37. 2+ plus prooxidants
38. Recent progress on regulation of the mitochondrial permeability transition pore: A cyclosporin-sensitive pore in the inner mitochondrial membrane
39. Inhibition of rat liver mitochondrial permeability transition by respiratory substrates
40. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells
41. Cyclosporin A protects hepatocytes against prooxidant-induced cell killing
42. Mitochondrial dysfunction is a primary event in glutamate excitotoxicity
43. Enzymatic mechanisms of superoxide production
44. Cyclosporin A-sensitive and insensitive mechanisms produce the permeability transition in mitochondria
45. The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition
46. Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-butylhydroperoxide: Protection by fructose, cyclosporin A and trifluoperazine
47. Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide
48. Catecholamine-derived aldehyde neurotoxins
49. Differences in the activation of the mitochondrial permeability transition among selective brain regions in the rat correlate with selective vulnerability
50. Cytochrome c release from brain mitochondria is independent of the mitochondrial permeability transition
51. The Parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism
52. Biochemical characterization of the mitochondrial permeability transition in isolated forebrain mitochondria
53. Cyclosporin A delays mitochondrial depolarization induced by N-methyl-D-aspartate in cortical neurons: Evidence of the mitochondrial permeability transition
54. Mitochondrial depolarization in glutamate-stimulated neurons: An early signal specific for excitotoxin exposure
55. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat
56. Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia
57. Changes in the bioenergetic state of rat hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects
58. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion
59. Dietary restriction augments protection against induction of the mitochondrial permeability transition
60. Detoxification of reactive aldehydes in mitochondria: Effect of age and dietary restriction
61. Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type
62. Accumulation of DOPEGAL, the neurotoxic MAO-A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer's disease: Mechanism of neuron death
63. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
64. Mitochondrial DNA transmission of the mitochondrial defect in parkinson's disease
65. L-dopa induced neurotoxicity